8-methanesulfonyl-6-methyl-3-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazine | 1111269-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 8-methanesulfonyl-6-methyl-3-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazine
• 英文别名: 6-methyl-8-methylsulfonyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine
• CAS: 1111269-94-3
• 化学式: C₁₁H₁₁N₅O₂S
• 分子量: 277.307
• InChiKey: DQAGMDUVKQKYRR-UHFFFAOYSA-N

物化性质

• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-methanesulfonyl-6-methyl-3-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazine 在 水 、 sodium hydride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-chloro-4-[[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino]benzoic acid
  参考文献：
  名称：

  Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors

  摘要：

  A series of substituted imidazo[1,2-a]pyrazin-8-amines were discovered as novel breast tumor kinase (Brk)/protein tyrosine kinase 6 (PTK6) inhibitors. Tool compounds with low-nanomolar Brk inhibition activity, high selectivity towards other kinases and desirable DMPK properties were achieved to enable the exploration of Brk as an oncology target. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.101
• 作为产物：
  描述：

  6-溴-8-甲硫基咪唑并[1,2-A]吡嗪 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 N-碘代丁二酰亚胺 、 四(三苯基膦)钯 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 8-methanesulfonyl-6-methyl-3-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazine
  参考文献：
  名称：

  Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors

  摘要：

  A series of substituted imidazo[1,2-a]pyrazin-8-amines were discovered as novel breast tumor kinase (Brk)/protein tyrosine kinase 6 (PTK6) inhibitors. Tool compounds with low-nanomolar Brk inhibition activity, high selectivity towards other kinases and desirable DMPK properties were achieved to enable the exploration of Brk as an oncology target. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.101

文献信息

• ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT
  申请人：Basso-Porcaro Andrea Dawn

  公开号：US20100249030A1

  公开（公告）日：2010-09-30

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.

  本发明涉及一种通过预先使用抗有丝分裂剂，然后再使用至少一种极化素激酶抑制剂来治疗癌症的方法。详细说明了在本发明治疗中有用的抗有丝分裂剂和极化素激酶抑制剂。
• WO2008/156614
  申请人：——

  公开号：——

  公开（公告）日：——
• Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors
  作者：Zhaoyang Meng、Bheemashankar A. Kulkarni、Angela D. Kerekes、Amit K. Mandal、Sara J. Esposite、David B. Belanger、Panduranga Adulla Reddy、Andrea D. Basso、Seema Tevar、Kimberly Gray、Jennifer Jones、Elizabeth B. Smith、Ronald J. Doll、M. Arshad Siddiqui

  DOI：10.1016/j.bmcl.2010.10.008

  日期：2011.1

  Our continued effort toward the development of the imidazo[1,2-a] pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified. (C) 2010 Elsevier Ltd. All rights reserved.
• [EN] IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES COMME INHIBITEURS DE LA PROTÉINE KINASE
  申请人：SCHERING CORP

  公开号：WO2008156614A2

  公开（公告）日：2008-12-24

  [EN] In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
  [FR] Dans ses nombreux modes de réalisation, la présente invention porte sur une nouvelle classe de composés imidazopyrazine comme inhibiteurs de protéine et/ou d'Aurora kinases, sur des procédés de préparation de ces composés, sur des compositions pharmaceutiques comprenant un ou plusieurs de ces composés, sur des procédés de préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés et sur des procédés de traitement, de prévention, d'inhibition ou d'amélioration d'une ou plusieurs maladies associées aux protéines ou Aurora kinases à l'aide de ces composés et de ces compositions pharmaceutiques.
• [EN] ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT<br/>[FR] COMBINAISON D'AGENT ANTIMITOTIQUE ET D'INHIBITEUR DE L'AURORA KINASE COMME TRAITEMENT ANTI-CANCER
  申请人：SCHERING CORP

  公开号：WO2009017701A2

  公开（公告）日：2009-02-05

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.